montelukast sodium

FDA Drug Profile — montelukast sodium, SINGULAIR

montelukast sodium is listed in the FDA National Drug Code directory with 27 NDC codes, marketed under brand names including montelukast sodium, SINGULAIR. Available dosage forms: tablet, chewable, tablet, film coated, granule, powder.

Drug details

Generic Name
montelukast sodium
Brand Names
montelukast sodium, SINGULAIR
Application Number
ANDA204093
Sponsor
Camber Pharmaceuticals, Inc.
NDC Codes
27
Dosage Forms
TABLET, CHEWABLE, TABLET, FILM COATED, GRANULE, POWDER
Routes
ORAL
Active Ingredients
MONTELUKAST, MONTELUKAST SODIUM

Indications and Usage

1 INDICATIONS AND USAGE Montelukast sodium is a leukotriene receptor antagonist indicated for: • Prophylaxis and chronic treatment of asthma in patients 2 years of age and older ( 1.1 ). • Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older ( 1.2 ). • Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 2 years of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies ( 1.3 ). Limitations of Use: • Not indicated to treat an acute asthma attack ( 5.2 ). 1.1 Asthma Montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. 1.2 Exercise-Induced Bronchoconstriction (EIB) Montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older. 1.3 Allergic Rhinitis Montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. Because the benefits of montelukast sodium may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see Warnings and Precautions ( 5.1 )], reserve use for patients who have an inadequate response or intolerance to alternative therapies. 1.4 Limitations of Use Montelukast Sodium is not indicated for the treatment of an acute asthma attack..

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.